The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Dusodril     2-diethylaminoethyl 2-(naphthalen-1...

Synonyms: nafronyl, Dubimax, Praxilene, Iridus, Oxalte, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Praxilene


Psychiatry related information on Praxilene


High impact information on Praxilene


Chemical compound and disease context of Praxilene


Biological context of Praxilene


Anatomical context of Praxilene


Associations of Praxilene with other chemical compounds

  • Serotonin-induced contractility in human saphenous vein is inhibited by naftidrofuryl [24].
  • Exposure of these mitochondria to 0.1 to 1 microM Naftidrofuryl significantly restored the succinate dehydrogenase activity [12].
  • We investigated the effects of age and nafidrofuryl oxalate (Naftidrofuryl), a 5-HT2 antagonist, on neurotransmission and transduction systems in the gerbil hippocampus using quantitative autoradiography [25].
  • Specific, sensitive, reversed-phase high-pressure liquid chromatographic assays of nafronyl (I) and its acidic metabolite and hydrolysis product (II) were developed in aqueous solutions and in biological fluids with sensitivities of 100 ng/ml using butacaine as the internal standard and spectrophotometric detection of 224 nm [26].
  • The effects of naftidrofuryl (Praxilene) on exercise-induced tissue ischaemia was objectively assessed by continuously measuring the tcpO2 in 30 patients during three treadmill tests over a 3-month period in a randomized double-blind, placebo controlled, parallel group study [27].

Gene context of Praxilene

  • Effect of endothelin-1 on human platelet shape change: reversal of activation by naftidrofuryl [28].
  • On the other hand, the 5-HT2 antagonist naftidrofuryl failed to protect the brain tissue significantly against ischemic brain damage [29].
  • Although no influence of naftidrofuryl on the rate of growth of neurites was observed, the drug enhanced the relative amount of the high molecular weight neurofilament subunit without affecting the concentration of a microtubule-associated protein, MAP2 [30].
  • Recently, an additional mode of action of naftidrofuryl (i.e., mixed endothelin receptor antagonism) has been suggested [31].
  • Naftidrofuryl significantly improved the physiological function of the liver cells as reflected by indocyanine green (ICG) clearance by the liver (t = 2.61; p less than or equal to 0.02) and also caused a larger fall in raised serum levels of gamma glutamyl transpeptidase (GGT) than did the placebo injections [32].

Analytical, diagnostic and therapeutic context of Praxilene


  1. Effect of prolonged and intermittent hypoxia on some cerebral enzymatic activities related to energy transduction. Dagani, F., Marzatico, F., Curti, D., Zanada, F., Benzi, G. J. Cereb. Blood Flow Metab. (1984) [Pubmed]
  2. Effects of agents used in the pharmacotherapy of cerebrovascular disease on the oxygen consumption of isolated cerebral mitochondria. Nowicki, J.P., MacKenzie, E.T., Spinnewyn, B. J. Cereb. Blood Flow Metab. (1982) [Pubmed]
  3. Effects of naftidrofuryl on breathlessness and exercise tolerance in chronic bronchitis. Williams, A.J., Osman, J., Skinner, C. Thorax (1982) [Pubmed]
  4. Effects of naftidrofuryl on hypoxia-induced activation and mortality of human endothelial cells. Michiels, C., Arnould, T., Janssens, D., Alexandre, I., Houbion, A., Remacle, J. J. Pharmacol. Exp. Ther. (1993) [Pubmed]
  5. The importance of personality measurement in the assessment of response to treatment for ischaemic rest pain. Wong, A.L., McBain, G.C. The British journal of surgery. (1980) [Pubmed]
  6. The efficacy of naftidrofuryl in patients with vascular or mixed dementia. Gold, M. Clinical therapeutics. (2000) [Pubmed]
  7. Naftidrofuryl in the treatment of mild senile dementia. A double-blind study. Grossmann, W.M., Standl, A., May, U., van Laak, H.H., Hirche, H. Pharmacopsychiatry (1990) [Pubmed]
  8. Naftidrofuryl in the treatment of vascular dementia. Möller, H.J., Hartmann, A., Kessler, C., Rainer, M., Brown, T., Gamand, S., Lehert, P. European archives of psychiatry and clinical neuroscience. (2001) [Pubmed]
  9. Naftidrofuryl in the treatment of subacute stroke. Capon, A., Lehert, P., Opsomer, L. J. Cardiovasc. Pharmacol. (1990) [Pubmed]
  10. Naftidrofuryl-driven regulation of endothelial ICAM-1 involves nitric oxide. Marconi, A., Darquenne, S., Boulmerka, A., Mosnier, M., D'Alessio, P. Free Radic. Biol. Med. (2003) [Pubmed]
  11. Effects of cerebroprotective agents on cerebral blood flow and on postischemic energy metabolism in the rat brain. Bielenberg, G.W., Beck, T., Sauer, D., Burniol, M., Krieglstein, J. J. Cereb. Blood Flow Metab. (1987) [Pubmed]
  12. In vitro effect of naftidrofuryl oxalate on cerebral mitochondria impaired by microsphere-induced embolism in rats. Takeo, S., Miyake, K., Minematsu, R., Tanonaka, K., Konishi, M. J. Pharmacol. Exp. Ther. (1989) [Pubmed]
  13. Effects of naftidrofuryl oxalate on microsphere-induced changes in acetylcholine and amino acid content of rat brain regions. Taguchi, T., Takagi, N., Miyake, K., Tanonaka, K., Okada, M., Kajihara, H., Takeo, S. Experimental brain research. Experimentelle Hirnforschung. Expérimentation cérébrale. (1994) [Pubmed]
  14. Effects of naftidrofuryl oxalate, a 5-HT2 antagonist, on neuronal damage and local cerebral blood flow following transient cerebral ischemia in gerbils. Fujikura, H., Kato, H., Araki, T., Ban, H., Hasegawa, Y., Kogure, K. Brain Res. (1994) [Pubmed]
  15. Serotonin, 5-HT2 receptors, and their blockade by naftidrofuryl: a targeted therapy of vascular diseases. Wiernsperger, N.F. J. Cardiovasc. Pharmacol. (1994) [Pubmed]
  16. Cost effectiveness of cilostazol compared with naftidrofuryl and pentoxifylline in the treatment of intermittent claudication in the UK. Guest, J.F., Davie, A.M., Clegg, J.P. Current medical research and opinion. (2005) [Pubmed]
  17. Naftidrofuryl oxalate improves impaired brain glucose metabolism after microsphere-induced cerebral embolism in rats. Takeo, S., Tanonaka, R., Miyake, K., Tanonaka, K., Taguchi, T., Kawakami, K., Ono, M., Hiramatsu, M., Okano, K. J. Pharmacol. Exp. Ther. (1991) [Pubmed]
  18. Bioanalyses and pharmacokinetics of nafronyl in the dog. Garrett, E.R. Journal of pharmaceutical sciences. (1984) [Pubmed]
  19. A memory assessment technique for use in geriatric psychopharmacology: drug efficacy trial with naftidrofuryl. Branconnier, R.J., Cole, J.O. Journal of the American Geriatrics Society. (1977) [Pubmed]
  20. Drugs affecting the inner ear. A review of their clinical efficacy, mechanisms of action, toxicity, and place in therapy. Norris, C.H. Drugs (1988) [Pubmed]
  21. Rat cortex synaptic and nonsynaptic mitochondria: enzymatic characterization and pharmacological effects of naftidrofuryl. Dagani, F., Gorini, A., Polgatti, M., Villa, R.F., Benzi, G. J. Neurosci. Res. (1983) [Pubmed]
  22. Effects of naftidrofuryl on adrenergic nerves, endothelium and smooth muscle in isolated canine blood vessels. Zander, J.F., Aarhus, L.L., Katusic, Z.S., Rubanyi, G.M., Vanhoutte, P.M. J. Pharmacol. Exp. Ther. (1986) [Pubmed]
  23. Beneficial effects of naftidrofuryl oxalate on brain regional energy metabolism after microsphere-induced cerebral embolism. Miyake, K., Taguchi, T., Tanonaka, K., Horiguchi, T., Takagi, N., Takeo, S. J. Pharmacol. Exp. Ther. (1992) [Pubmed]
  24. Serotonin-induced contractility in human saphenous vein is inhibited by naftidrofuryl. Vashisht, R., Sian, M., Sharp, E.J., Leathard, H.L., O'Malley, M.K. The British journal of surgery. (1992) [Pubmed]
  25. Effects of naftidrofuryl oxalate, a 5-HT2 antagonist, on neurotransmission and transduction systems in the gerbil hippocampus. Ban, H., Kato, H., Araki, T., Fujikura, H., Hasegawa, Y., Kogure, K. Brain Res. (1994) [Pubmed]
  26. Prediction of stability in pharmaceutical preparations XVIII: application of high-pressure liquid chromatographic assays to study of nafronyl stability and bioanalysis. Garrett, E.R., Barbhaiya, R. Journal of pharmaceutical sciences. (1981) [Pubmed]
  27. The effect of naftidrofuryl on transcutaneous oxygen tension during a treadmill test in patients with peripheral arterial occlusive disease. Mouren, X., Caillard, P., Bensoussan, J.J., Massonneau, M., Gamand, S., Stevens, W.H. Vascular medicine (London, England) (1998) [Pubmed]
  28. Effect of endothelin-1 on human platelet shape change: reversal of activation by naftidrofuryl. Jagroop, I.A., Mikhailidis, D.P. Platelets (2000) [Pubmed]
  29. Effects of serotonergic drugs in experimental brain ischemia: evidence for a protective role of serotonin in cerebral ischemia. Prehn, J.H., Welsch, M., Backhauss, C., Nuglisch, J., Ausmeier, F., Karkoutly, C., Krieglstein, J. Brain Res. (1993) [Pubmed]
  30. Naftidrofuryl, a putative activator of neuron survival, stimulates the expression of neurofilament heavy subunit in cultivated spinal cord neurons from chicken. Leterrier, J.F., Maher, A., Eyer, J., Gou, J.P., Haddad, K., Pouplard-Berthelaix, A. Biochem. Biophys. Res. Commun. (1994) [Pubmed]
  31. Naftidrofuryl exerts antiserotonergic but no endothelin-receptor blocking effects in AS4.1 cells, juxtaglomerular cells and isolated perfused rat kidneys. Endemann, D., Schweda, F., Stubanus, M., Ittner, K.P., Fischereder, M., Kammerl, M.C., Krämer, B.K. J. Cardiovasc. Pharmacol. (2002) [Pubmed]
  32. The effect of Naftidrofuryl on ethanol-induced liver damage in chronic alcoholic patients. Majumdar, S.K., Shaw, G.K., O'Gorman, P., Thomson, A.D. Drug and alcohol dependence. (1982) [Pubmed]
  33. Effects of delayed treatment with nafronyl oxalate on microsphere embolism-induced changes in monoamine levels of rat brain regions. Takagi, N., Miyake, K., Ohiwa, A., Nukaga, R., Takeo, S. Br. J. Pharmacol. (1996) [Pubmed]
  34. Efficacy of naftidrofuryl in patients with vascular or mixed dementia: results of a multicenter, double-blind trial. Emeriau, J.P., Lehert, P., Mosnier, M. Clinical therapeutics. (2000) [Pubmed]
  35. In vivo effect of naftidrofuryl on 5-hydroxytryptamine-mediated constriction in rat peripheral microcirculation. Koch, L.G., Alsip, N.L., Feige, B.D., Wead, W.B., Harris, P.D. Eur. J. Pharmacol. (1994) [Pubmed]
  36. Determination of naftidrofuryl in the plasma of humans by high-performance liquid chromatography. Brodie, R.R., Chasseaud, L.F., Taylor, T., Hunter, J.O., Ciclitira, P.J. J. Chromatogr. (1979) [Pubmed]
WikiGenes - Universities